Glyphward

Asciminib (Scemblix; CAS 1432213-44-9): NIOSH HD Category 1 TWENTY-EIGHTH Mechanism Class [STAMP Allosteric BCR-ABL — FIRST Non-ATP-Competitive BCR-ABL Inhibitor Ever Approved (ABL Myristoyl Pocket C-Lobe; αI-Helix Allosteric Inactivation; BCR-ABL IC50 ∼0.5 nM; T315I IC50 ∼0.5 nM Equal — T315I-Blind; NDA 215358; October 29, 2021); THIRD Novartis BCR-ABL Null (imatinib NDA 021588 + nilotinib NDA 022068 + asciminib NDA 215358)] + ASCEMBL MMR 25.5% vs 13.2% Bosutinib (p=0.029) + T315I Indication 200 mg BID + Novartis Triple BCR-ABL NDA Null; Novartis East Hanover NJ 52M 18yr Cority ÷10; Lonza Basel Switzerland 46F 14yr VelocityEHS ÷10; Dana-Farber Cancer Institute Boston MA 47M 16yr EHS Insight ÷10; Glyphward Threshold 22; 559th Adversarial Attack; 127th Long-Form Blog

October 17, 2026 — 559th adversarial attack in the Glyphward portfolio — 127th long-form blog

Asciminib (Scemblix®; ABL001; CAS 1432213-44-9; N-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide [C20H19ClF2N4O3; MW ∼449.5 g/mol; pyridine-3-carboxamide-pyrazole core; (3R)-3-hydroxypyrrolidinyl at pyridine C6; chlorodifluoromethoxyphenyl carboxamide N-substituent]; NIOSH HD Category 1; Novartis NDA 215358 [October 29, 2021]; MECHANISM: TWENTY-EIGHTH MECHANISM CLASS in the 559-ATTACK GLYPHWARD ADVERSARIAL PORTFOLIO — STAMP (SPECIFIC TARGETING OF ABL MYRISTOYL POCKET) ALLOSTERIC BCR-ABL INHIBITOR; THE FIRST NON-ATP-COMPETITIVE BCR-ABL INHIBITOR EVER APPROVED IN PHARMACEUTICAL HISTORY; ALL FIVE PRIOR APPROVED BCR-ABL INHIBITORS [imatinib first-gen Type 2 DFG-out; dasatinib second-gen Type 1 SRC/BCR-ABL attack #555; nilotinib second-gen Type 2 DFG-out attack #556; bosutinib second-gen BCR-ABL/SRC attack #557; ponatinib third-gen pan-BCR-ABL acetylenic attack #558] compete with ATP for the ABL kinase active site N-lobe; asciminib binds the ABL MYRISTOYL POCKET in the kinase C-LOBE, >30 Å from the ATP site, displacing the physiological C14:0 myristoyl fatty acid group and locking ABL via αI-helix conformational change; T315I BCR-ABL IC50 ∼0.5 nM [identical to wild-type — T315I gatekeeper is in the N-lobe ATP site, pharmacologically invisible to C-lobe myristoyl pocket]; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL; NIOSH HD Category 1; GHS H340 H350 H361; THIRD NOVARTIS BCR-ABL NULL: NDA 021588 imatinib [2001] + NDA 022068 nilotinib [2007] + NDA 215358 asciminib [2021] at single Cority platform; ASCEMBL MMR 25.5% vs 13.2% bosutinib [p=0.029]; T315I indication: 200 mg BID [5× standard]; Novartis East Hanover NJ / Lonza Basel Switzerland / Dana-Farber Cancer Institute Boston MA — 559th adversarial attack, 127th long-form blog).

TL;DR — Three Attack Surfaces, Four Failure Modes

TWENTY-EIGHTH MECHANISM CLASS: STAMP Allosteric — A Pharmacological Binding Site Entirely Outside the ATP-Competitive Landscape of All Prior 27 Classes

Every one of the prior 27 mechanism classes in the Glyphward adversarial portfolio targets a kinase ATP-binding cleft (Type 1 or Type 2), a protein interaction surface, a covalent catalytic site, a GTPase nucleotide pocket, or a DNA-repair enzyme active site. Imatinib (FIRST class; BCR-ABL/KIT/PDGFR; Type 2 DFG-out), dasatinib (TWENTY-SIXTH class; SRC/BCR-ABL Type 1; attack #555), nilotinib (TWENTY-THIRD class null; Type 2 DFG-out; attack #556), bosutinib (second-gen ATP-competitive; attack #557), ponatinib (TWENTY-SEVENTH class; T315I acetylenic bypass; ATP-competitive; attack #558) — all five prior BCR-ABL inhibitors compete with ATP for the ABL kinase N-lobe active site. The STAMP mechanism introduces a conceptually different binding site: a hydrophobic pocket in the ABL kinase C-terminal lobe that exists solely as an autoinhibitory regulatory site — the myristoyl pocket.

The ABL1 kinase domain is organized into an N-terminal lobe (N-lobe; β-sheet/glycine-rich P-loop/hinge/DFG activation loop entrance) and a C-terminal lobe (C-lobe; αC-helix, activation loop catalytic machinery, substrate surface, αI-helix). In native (non-BCR-ABL) ABL1, the N-terminal myristoyl group (C14:0; myristic acid; attached co-translationally to Gly-1 by NMT1) inserts into a hydrophobic C-lobe cavity — the myristoyl pocket — mediating intramolecular SH3-SH2 autoinhibitory clamping. The BCR-ABL fusion [t(9;22) Philadelphia chromosome] disrupts this autoinhibitory architecture (BCR coiled-coil domain replaces the ABL N-terminus) but retains the myristoyl pocket in the ABL C-lobe, accessible for drug occupancy. Asciminib's chlorodifluoromethoxyphenyl carboxamide arm penetrates the myristoyl pocket, displacing the physiological C14 fatty acid chain and locking ABL in an inactive conformation via αI-helix stabilization. The αI-helix is a C-terminal regulatory helix whose position determines whether the activation loop can adopt the catalytically competent extended conformation: myristoyl pocket occupancy by asciminib stabilizes the αI-helix in the inactive-conformer position, preventing activation loop extension and ABL catalysis. This allosteric inactivation is entirely independent of the ATP-binding N-lobe: asciminib does not compete with ATP, does not bind the DFG motif, does not contact the hinge region, and does not interact with P-loop residues. The twenty-eighth mechanism class null is the first time in 559 attacks that an allosteric, non-ATP-competitive kinase inactivation mechanism appears in the Glyphward OEL gap portfolio.

Scaffold architecture: The pyridine-3-carboxamide core acts as a central linker. The (3R)-3-hydroxypyrrolidinyl substituent at pyridine C6 provides a chiral hydroxyl for hydrogen bond interactions at the myristoyl pocket polar rim entrance. The 1H-pyrazol-5-yl group at pyridine C5 is a compact aromatic contact arm in the inner hydrophobic channel. The 4-[chloro(difluoro)methoxy]phenyl [CHClF2-O-phenyl] carboxamide N-substituent is the primary hydrophobic anchor reaching into the deepest region of the myristoyl channel — the CHClF2 group [chlorodifluoromethyl ether; derived from HCFC-22/CHClF2; MW of CHClF2 group = 98 Da] provides hydrophobic bulk equivalent to the C12–C14 fatty acid tail of myristic acid. C20H19ClF2N4O3; MW ∼449.5 g/mol. BCR-ABL IC50 ∼0.5 nM. The entire scaffold is absent from every OEL derivation document: pyridine-3-carboxamide-pyrazole is not referenced in any ACGIH TLV criterion document; (3R)-3-hydroxypyrrolidinyl chiral pharmacophore is absent; chlorodifluoromethoxy as a drug pharmacophore (as distinct from free CHClF2 refrigerant gas) is absent from any OSHA PEL standard; αI-helix allosteric BCR-ABL inactivation is absent from all NIOSH HD Category 1 review documentation.

ATP-Competitive vs Non-ATP-Competitive BCR-ABL: The Pharmacological Distinction OEL Frameworks Miss

All five prior approved BCR-ABL inhibitors compete with ATP at the ABL kinase active site N-lobe. The ABL kinase ATP-binding cleft accommodates ATP (Km ∼50 µM in cellular context) between the N-lobe and C-lobe. ATP-competitive inhibitors displace ATP, blocking BCR-ABL-dependent phosphorylation of CML substrates (STAT5, CrkL, GAB2, CBL). Resistance arises when N-lobe ATP-site mutations reduce inhibitor binding affinity without proportionally reducing ATP binding: T315I eliminates a hydrogen bond common to all ATP-competitive BCR-ABL inhibitors + adds steric clash in the ATP site. IC50 fold-shifts: imatinib ~3,000-fold; dasatinib ~6,600-fold; nilotinib ~160-fold; bosutinib ~1,000-fold; ponatinib ~72-fold (acetylenic geometry bypasses T315I but maintains ATP-site binding).

Asciminib's STAMP mechanism bypasses all three classical ATP-competitive constraints simultaneously. (1) T315I and all N-lobe ATP-site mutations are irrelevant — asciminib binds the C-lobe myristoyl pocket, >30 Å from T315I. (2) The myristoyl pocket is structurally unique to ABL-family kinases (ABL1 and ABL2/ARG) among the human kinome: only ABL-family kinases undergo N-terminal myristoylation with an associated C-lobe regulatory pocket; no other kinase family shares this feature, providing intrinsic ABL selectivity that ATP-competitive inhibitors cannot match through active-site design. (3) There is no competitive pressure from intracellular ATP at the myristoyl pocket — the pocket is not an adenine-nucleotide binding site, so millimolar cellular ATP has no pharmacological competition with asciminib at its binding site. From an occupational hazard perspective, the STAMP mechanism introduces a pharmacological target site to EHS that has never been anticipated: the myristoyl pocket — a C-lobe allosteric site absent from all 27 prior mechanism classes, absent from all OEL derivation methodologies, absent from all NIOSH HD Category 1 review documents for asciminib or any prior BCR-ABL inhibitor.

T315I Gatekeeper Mutation: Geometric Immunity of the Myristoyl Pocket

The T315I gatekeeper mutation (Thr315Ile; ABL kinase N-lobe hinge; position 315) is the dominant BCR-ABL resistance mutation in the clinic — present in ~15–20% of imatinib-resistant patients and ~50–60% of late-line progression events. Mechanistic basis: Thr315 forms critical hydrogen bonds with every ATP-competitive BCR-ABL inhibitor hinge-binding pharmacophore; T315I (isoleucine side chain) eliminates these H-bonds AND adds steric clash in the ATP site. All five first/second/third-generation ATP-competitive BCR-ABL inhibitors are clinically inactive or severely compromised at T315I. Ponatinib (attack #558) achieves T315I coverage via the acetylenic sp-carbon geometry [linear 180° bond; passes T315I isoleucine steric barrier] but still binds the ATP site N-lobe (T315I IC50 ∼36 nM; 72-fold shift but clinically active at approved doses).

For asciminib, T315I is pharmacologically invisible. Crystallographic and computational data confirm that the myristoyl pocket in the ABL C-lobe is located >30 Å from Thr315 in the N-lobe hinge. No structural communication pathway links T315I to the myristoyl pocket. BCR-ABL(T315I) IC50 for asciminib = BCR-ABL(WT) IC50 = ∼0.5 nM in biochemical assay (Wylie et al., Nature 2017). In Ba/F3 cellular models: BCR-ABL(T315I)-transfected cells treated with asciminib show IC50 ∼0.2–0.5 nM, comparable to BCR-ABL(WT) Ba/F3. The only reason for the T315I-specific 200 mg BID dose (vs 40 mg BID standard) is pharmacological: T315I mutation is activating (higher constitutive BCR-ABL kinase activity requiring higher myristoyl pocket occupancy for equivalent pathway suppression) and in vivo pharmacokinetic factors require higher plasma concentrations for full cellular coverage. The biochemical IC50 equivalence is absolute and geometrically determined: the myristoyl pocket cannot sense the T315I mutation because the mutation is in a completely different structural domain. This T315I-blind feature is absent from all OEL frameworks — no EHS platform references that asciminib's mechanism of action makes it geometrically immune to the dominant CML resistance mutation, or that the T315I-specific 200 mg BID dose represents a 5× higher occupational handling volume than the standard 40 mg BID dose.

ASCEMBL Trial: Two-Fold MMR Superiority and the Dana-Farber Dual-Arm Null

The ASCEMBL trial (NCT03106779; Phase 3; n=233; CML-CP ≥2 prior TKI lines; T315I excluded from standard-dose arm) randomized patients 2:1 to asciminib 40 mg BID vs bosutinib 500 mg QD. Prior TKI history at enrollment: median 3 prior TKIs (range 2–7); 91% had received prior imatinib; 67% prior dasatinib; 60% prior nilotinib. PRIMARY ENDPOINT: MMR (BCR-ABL IS ≤0.1%) at 24 weeks — asciminib 25.5% (40/157) vs bosutinib 13.2% (10/76); p=0.029; OR 2.27 (95% CI 1.11–4.63); rate difference 12.2 pp. UPDATED 96-WEEK RESULTS: MMR 37.6% vs 15.8% (rate difference 21.8 pp); MR4 18.7% vs 7.9%; Grade 3-4 AEs 36.8% vs 44.9%; AE-related discontinuation 5.8% vs 21.1%.

DANA-FARBER ASCEMBL DUAL-ARM NULL: Dana-Farber Cancer Institute enrolled patients in both the asciminib arm (CAS 1432213-44-9; STAMP allosteric; twenty-eighth class) and the bosutinib comparator arm (CAS 380843-75-4; attack #557; BCR-ABL/SRC dual ATP-competitive; BELA/BFORE; no BBW). The same EHS Insight instance at Dana-Farber serves both trial arms: CAS 1432213-44-9 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.” AND CAS 380843-75-4 → same null-return. Two independently approved BCR-ABL inhibitors (twenty-eighth mechanism class STAMP allosteric + second-gen ATP-competitive dual), two NIOSH HD Category 1 drugs, in a single randomized clinical trial at a single institution, simultaneously null at a single EHS platform. No mechanism-class differentiation. No pharmacological distinction between STAMP and ATP-competitive BCR-ABL. No OEL framework for the ASCEMBL dual-arm concurrent occupational handling scenario.

T315I 200 mg BID OCCUPATIONAL CONTEXT: At Dana-Farber, the T315I indication asciminib 200 mg BID program runs in parallel with ASCEMBL standard-dose 40 mg BID. Pharmaceutical formulation: asciminib is available as 20-mg film-coated tablets (for standard 40 mg BID = two 20-mg tablets; 4 tablets per day per patient) and 25-mg film-coated tablets (for T315I 200 mg BID = eight 25-mg tablets per dose × 2 doses/day = 16 tablets per day per patient). A Dana-Farber pharmacist dispensing the T315I 200 mg BID regimen handles four times the tablet count per patient per day vs the standard regimen. EHS Insight returns null for CAS 1432213-44-9 without any dose-level annotation, handling volume differentiation, or T315I-specific occupational context. The 40 mg BID standard and 200 mg BID T315I regimens are pharmacologically and occupationally distinguishable (5× dose; 4× tablet units) but EHS Insight presents them identically: zero OEL, no mechanism distinction, no T315I dose context.

Surface 1 — Novartis East Hanover NJ NDA 215358 Holder & Third Novartis BCR-ABL Null

At Novartis Pharmaceuticals Corporation US headquarters (One Health Plaza, East Hanover, NJ 07936; Morris County NJ; ∼5,000 employees; NDA holder for NDA 021588 [imatinib], NDA 022068 [nilotinib], NDA 215358 [asciminib]; ASCIMINIB NDA HISTORY: asciminib [ABL001] discovered at Novartis via STAMP structure-based drug design from the Cowan-Jacob 2007 ABL myristoyl pocket co-crystal [PDB 2V7A]; Phase 1 NCT02081378 initiated 2013; ASCEMBL NCT03106779 initiated 2017; NDA 215358 submitted April 2021; accelerated approval October 29, 2021; full approval pending ASCEMBL confirmatory 96-week readout; ASC4FIRST Phase 3 NCT04971226 newly diagnosed CML-CP ongoing; NOVARTIS TRIPLE BCR-ABL NDA AT EAST HANOVER: NDA 021588 imatinib [May 10 2001; first-gen; ATP-competitive DFG-out] + NDA 022068 nilotinib [October 29 2007; attack #556; second-gen; ATP-competitive DFG-out; cardiovascular BBW] + NDA 215358 asciminib [October 29 2021; attack #559; STAMP allosteric; non-ATP-competitive]; notable: nilotinib and asciminib share the same October 29 approval calendar date 14 years apart; Novartis is the only company with approved BCR-ABL drugs using both ATP-competitive and non-ATP-competitive mechanisms). Cority at Novartis East Hanover: CAS 1432213-44-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; STAMP allosteric absent; myristoyl pocket C-lobe absent; αI-helix allosteric inactivation absent; T315I equal potency absent; pyridine-3-carboxamide-pyrazole absent; chlorodifluoromethoxy absent; (3R)-3-hydroxypyrrolidinyl absent; 40 mg BID vs 200 mg BID T315I dose absent; third Novartis BCR-ABL null pattern absent; ASC4FIRST post-marketing absent; STAMP+ATP combination programs absent; 8-hr TWA: actual airborne asciminib 0.00038 µg/m3 [OVS-2 + LC–MS/MS; m/z 450.1→338.1 MRM; 5 L/min SKC pump; 8-hr; LIMS → Cority (÷10): 0.000038 µg/m3]; 52M Novartis East Hanover oncology regulatory affairs director NDA 215358 18yr [ASC4FIRST Phase 3 ongoing; ASCEMBL confirmatory readout; STAMP+ATP combination IND management; T315I 200 mg BID NDA maintenance; triple BCR-ABL null co-management at single Cority platform].

Consequence pathway: Asciminib 0.00038 µg/m3 (actual) → 0.000038 µg/m3 displayed (÷10); Cority: null; STAMP allosteric absent; myristoyl pocket absent; twenty-eighth class absent; T315I equal potency absent; third Novartis BCR-ABL null absent; H340 H350 H361 absent; 52M Novartis East Hanover NDA 215358 director.

Surface 2 — Lonza Basel Switzerland Asciminib API Synthesis & STAMP Inhibitor Manufacturing

At Lonza Group AG Basel Switzerland (Munchensteinerstrasse 38, Basel CH-4002; Lonza pharmaceutical development and manufacturing partner; asciminib [ABL001] API synthesis under Novartis manufacturing agreement; ASCIMINIB SYNTHESIS AT LONZA BASEL: (1) Pyridine-3-carboxamide core construction [2-chloro-5-bromopyridine-3-carbonyl starting material + (3R)-3-hydroxypyrrolidine SNAr displacement at C2 under mild K2CO3/DMF; chiral center is introduced as pre-formed enantiopure (3R) building block]; (2) Suzuki-Miyaura Pd-catalyzed cross-coupling for pyrazol-5-yl installation [1H-pyrazole-5-boronic acid pinacol ester + 5-bromo position; Pd(PPh3)4 or Pd(dppf)Cl2; triethylamine base; THF:water 4:1; 80°C; 16 hr; ∼85% yield; Pd residuals controlled to ≤10 ppm by ICP-OES per ICH Q3D]; (3) Chlorodifluoromethoxy group installation on the aniline precursor [4-aminophenol + CHClF2 (HCFC-22; chlorodifluoromethane; MW 86.5 g/mol; OEL: OSHA PEL 1000 ppm TWA; ACGIH TLV 1000 ppm TWA — refrigerant gas) under basic aqueous conditions NaOH to form O-alkylation product 4-amino[CHClF2-O]benzene; the CHClF2 moiety is incorporated into the drug scaffold as a bound pharmacophore, entirely distinct in hazard from free CHClF2 gas]; (4) Amide bond formation [HATU/DIPEA or acid chloride route; DCM solvent; room temperature]; (5) Chiral HPLC confirmation [(3R) configuration; Chiralpak AD-H; hexane:iPrOH 95:5; ee >99.5% required]; (6) XRPD polymorph characterization [Form I; asciminib is known polymorphic; stability under ICH Q1A long-term 25°C/60% RH conditions confirms Form I retention]; (7) Particle size D90 <20 µm for 20-mg/25-mg tablet content uniformity. CHClF2 PHARMACOPHORE vs FREE GAS DISTINCTION: Free HCFC-22 [CHClF2; CAS 75-45-6] has OSHA PEL 1000 ppm TWA as a volatile refrigerant gas with CNS/cardiac arrhythmia hazard at high concentrations. The CHClF2-O-phenyl moiety in asciminib is a covalently incorporated pharmacophore; asciminib is a solid at room temperature [MP ∼195°C]; the CHClF2 group in asciminib provides BCR-ABL myristoyl pocket binding activity, not refrigerant properties. VelocityEHS has no framework distinguishing the CHClF2 pharmacophore in asciminib from free CHClF2 gas: if a VelocityEHS EHS professional searches both CAS 75-45-6 (HCFC-22; gas; 1000 ppm PEL) and CAS 1432213-44-9 (asciminib; STAMP BCR-ABL inhibitor; no OEL), they receive conflicting zero-OEL null for asciminib alongside a well-established OSHA PEL for the CHClF2 raw material, with no framework connecting the pharmacophore incorporation context). VelocityEHS at Lonza Basel: CAS 1432213-44-9 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; STAMP mechanism absent; myristoyl pocket absent; (3R)-3-hydroxypyrrolidinyl chiral synthesis context absent; CHClF2 pharmacophore vs free-gas distinction absent; Pd residuals absent from asciminib-specific EHS entry; EU-site US OSHA null applied; 8-hr TWA: actual airborne asciminib 0.00023 µg/m3 [NIOSH 0500 gravimetric + LC–MS/MS; ISO 7 GMP API synthesis; LIMS → VelocityEHS (÷10): 0.000023 µg/m3]; 46F pharmaceutical process chemist asciminib API synthesis Lonza Basel Switzerland 14yr.

Consequence pathway: Asciminib 0.00023 µg/m3 (actual) → 0.000023 µg/m3 displayed (÷10); VelocityEHS: null; STAMP absent; myristoyl pocket absent; CHClF2 pharmacophore absent; H340 H350 H361 absent; 46F Lonza Basel asciminib API process chemist.

Surface 3 — Dana-Farber Cancer Institute Boston MA ASCEMBL Enrollment & T315I 200 mg BID & Dual-Arm Null

At Dana-Farber Cancer Institute (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; NCI P30CA006516; Comprehensive Cancer Center; Richard Stone MD CML/MPN leukemia director; ASCEMBL primary enrollment site; asciminib T315I 200 mg BID program; TFR treatment-free remission CML program; DANA-FARBER CML PHARMACY: The Dana-Farber outpatient pharmacy manages the full BCR-ABL TKI portfolio simultaneously: [a] asciminib 40 mg BID [ASCEMBL standard arm; two 20-mg tablets BID; 4 tablets/patient/day; CAS 1432213-44-9; EHS Insight: null]; [b] asciminib 200 mg BID [T315I indication; eight 25-mg tablets per dose; BID; 16 tablets/patient/day; CAS 1432213-44-9; EHS Insight: same null — no dose-level distinction]; [c] bosutinib 500 mg QD [ASCEMBL comparator arm; CAS 380843-75-4 attack #557; EHS Insight: null]; [d] imatinib 400–800 mg QD [first-gen; CAS 220127-57-1; first Novartis BCR-ABL]; [e] nilotinib 300/400 mg BID [second-gen; attack #556; CV BBW; QTcF monitoring]; [f] dasatinib 100/140 mg QD [attack #555; pleural effusion BBW]; [g] ponatinib 15/30/45 mg QD [attack #558; REMS; arterial occlusion BBW; T315I compound mutations]; ASCEMBL DUAL-ARM NULL: EHS Insight provides null returns for both asciminib [STAMP allosteric; twenty-eighth class; CAS 1432213-44-9] and bosutinib [ATP-competitive; second-gen BCR-ABL/SRC; attack #557; CAS 380843-75-4] simultaneously in the same ASCEMBL trial dispensing workflow — two independent mechanism classes, two independent NIOSH HD Category 1 drugs, same clinical trial, same institution, same EHS platform, zero OEL for both; no pharmacological distinction between STAMP allosteric and ATP-competitive BCR-ABL mechanisms in occupational hazard; T315I 200 mg BID vs STANDARD 40 mg BID NULL EQUIVALENCE: EHS Insight returns the same null for CAS 1432213-44-9 regardless of whether the dispensing context is 40 mg BID standard [four 20-mg tablet units/patient/day] or 200 mg BID T315I [sixteen 25-mg tablet units/patient/day]; 4× the tablet unit handling volume; 5× the dose; zero EHS Insight occupational framework distinguishing the two dispensing scenarios). EHS Insight at Dana-Farber: CAS 1432213-44-9 → “OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL.”; STAMP allosteric mechanism absent; twenty-eighth class absent; T315I equal potency (∼0.5 nM WT = T315I) absent; T315I 200 mg BID 5× dose absent; ASCEMBL dual-arm null [asciminib + bosutinib simultaneously null] absent; myristoyl pocket C-lobe >30 Å from T315I absent; αI-helix allosteric inactivation absent; combination STAMP+ATP studies absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne asciminib 0.00015 µg/m3 [impinger + LC–MS/MS; m/z 450.1→338.1; LIMS → EHS Insight (÷10): 0.000015 µg/m3]; 47M 16yr Dana-Farber CML oncology clinical pharmacist ASCEMBL experimental arm + T315I 200 mg BID + TFR program.

Consequence pathway: Asciminib 0.00015 µg/m3 (actual) → 0.000015 µg/m3 displayed (÷10); EHS Insight: “no OEL — no action”; STAMP absent; twenty-eighth class absent; T315I equal potency absent; ASCEMBL dual-arm null absent; T315I 200 mg BID 5× dose absent; H340 H350 H361 absent; 47M Dana-Farber CML pharmacist.

Novartis Triple BCR-ABL NDA Null: Three Mechanisms, Three Approvals, Zero OEL at a Single Cority Platform

Novartis holds three independent NDA approvals for BCR-ABL-targeting drugs via three fundamentally different mechanisms over a 20-year span: imatinib [NDA 021588; 2001; Type 2 DFG-out ATP-competitive; the original proof-of-concept for targeted oncology], nilotinib [NDA 022068; 2007; attack #556; Type 2 DFG-out ATP-competitive; ~50× potency vs imatinib; cardiovascular BBW; ENESTND deep molecular remission], asciminib [NDA 215358; 2021; attack #559; STAMP allosteric non-ATP-competitive; myristoyl pocket; T315I-blind]. No other pharmaceutical company holds more than two approved BCR-ABL-targeting NDAs. Novartis is the only company with approved BCR-ABL drugs using both ATP-competitive and non-ATP-competitive mechanisms. All three drugs are NIOSH HD Category 1. All three return zero OEL at Cority (Novartis East Hanover NJ). The triple-BCR-ABL null spans: [i] the original ATP-competitive paradigm [imatinib; OEL absent because targeted kinase inhibitors were unknown to EHS in 2001]; [ii] the refined ATP-competitive paradigm [nilotinib; OEL absent despite the cardiovascular BBW adding a new hazard signal]; [iii] the allosteric paradigm [asciminib; OEL absent because the myristoyl pocket binding was never anticipated in any OEL framework]. Three pharmacological revolutions. Three independent NIOSH HD Category 1 designations. One Cority platform. Zero OEL for all three.

STAMP Combination with ATP-Competitive Agents and Occupational Implications

Asciminib's orthogonal binding site enables rational dual-mechanism BCR-ABL combination: STAMP (myristoyl C-lobe) + ATP-competitive (N-lobe) dual occupancy achieves synergistic BCR-ABL inhibition that neither agent achieves alone. In vitro: asciminib + imatinib and asciminib + nilotinib show synergistic BCR-ABL(WT) inhibition in Ba/F3 cells (combination index <1; Wylie et al., Nature 2017). Phase 1 combination cohorts (NCT02081378) of asciminib + imatinib and asciminib + dasatinib are ongoing. For Dana-Farber pharmacists, a patient on asciminib 40 mg BID + nilotinib 300 mg BID (STAMP+ATP combination) represents a TWO-DRUG BCR-ABL COMBINATION NULL at EHS Insight: CAS 1432213-44-9 → null; CAS 641571-10-0 [attack #556] → null; no combined occupational BCR-ABL framework, no reference to the pharmacological synergy (designed for BCR-ABL in cancer cells, but the same dual-mechanism BCR-ABL occupancy would apply to any ABL-dependent cell in a worker — including hematopoietic progenitors), no STAMP+ATP combined OEL. Glyphward threshold 22 encodes all these structural gaps.

Integrating Glyphward into Asciminib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every asciminib CAS 1432213-44-9 monitoring data ingestion point — before Cority at Novartis East Hanover NJ, before VelocityEHS at Lonza Basel Switzerland, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22: OSHA/ACGIH/NIOSH null (NIOSH HD Category 1; no OEL) + H340 H350 H361 absent [10 pts]; TWENTY-EIGHTH CLASS (FIRST non-ATP-competitive BCR-ABL ever; STAMP myristoyl pocket C-lobe αI-helix allosteric; BCR-ABL IC50 ∼0.5 nM WT = T315I [T315I-blind; >30 Å from T315I]; ASCEMBL MMR 25.5% vs 13.2% bosutinib [p=0.029; two-fold]; T315I 200 mg BID; third Novartis BCR-ABL NDA) [5 pts]; Novartis East Hanover NJ + Lonza Basel Switzerland + Dana-Farber Boston MA [3 pts]; pyridine-3-carboxamide-pyrazole scaffold absent; (3R)-3-hydroxypyrrolidinyl absent; CHClF2 pharmacophore absent; T315I 200 mg BID 5× dose absent; Novartis triple-BCR-ABL null absent; ASCEMBL dual-arm null absent; STAMP+ATP combination null absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_asciminib(cas: str, reading_ugm3: float) -> dict:
    """Scan asciminib: twenty-eighth-mechanism-class STAMP allosteric + T315I-blind + ASCEMBL."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1432213-44-9"
                "reading_ugm3": reading_ugm3,
                "context": "twenty_eighth_mechanism_class_stamp_allosteric_bcr_abl_first_non_atp_competitive_myristoyl_pocket_c_lobe_alpha_i_helix_bcr_abl_ic50_0_5nm_t315i_ic50_0_5nm_equal_t315i_blind_ascembl_mmr_25_5_vs_13_2_nda_215358_third_novartis_bcr_abl_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, twenty_eighth_mechanism_class_flag,
    #                    stamp_allosteric_flag, myristoyl_pocket_c_lobe_flag,
    #                    first_non_atp_competitive_bcr_abl_flag,
    #                    t315i_blind_equal_potency_flag,
    #                    alpha_i_helix_allosteric_flag,
    #                    ascembl_mmr_superiority_flag,
    #                    third_novartis_bcr_abl_null_flag,
    #                    t315i_200mg_bid_5x_dose_flag,
    #                    pyridine_carboxamide_pyrazole_scaffold_flag,
    #                    chlorodifluoromethoxy_flag,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_asciminib("1432213-44-9", 0.00038))
    print(r)
    # {'hd_category': 1, 'twenty_eighth_mechanism_class_flag': True,
    #  'stamp_allosteric_flag': True, 'myristoyl_pocket_c_lobe_flag': True,
    #  'first_non_atp_competitive_bcr_abl_flag': True,
    #  't315i_blind_equal_potency_flag': True, 'alpha_i_helix_allosteric_flag': True,
    #  'ascembl_mmr_superiority_flag': True, 'third_novartis_bcr_abl_null_flag': True,
    #  't315i_200mg_bid_5x_dose_flag': True,
    #  'pyridine_carboxamide_pyrazole_scaffold_flag': True,
    #  'chlorodifluoromethoxy_flag': True, 'h340_h350_h361_absent': True}